Evaluation of a new hepatitis B virus surface antigen rapid test with improved sensitivity
- PMID: 18701669
- PMCID: PMC2566085
- DOI: 10.1128/JCM.00498-08
Evaluation of a new hepatitis B virus surface antigen rapid test with improved sensitivity
Abstract
A new rapid immunochromatographic assay based on the signal amplification system (SAS) has been developed by Diagnostics for the Real World (Europe) Ltd. for the detection of hepatitis B virus surface antigen (HBsAg) in plasma or serum specimens. The SAS format features enhanced sensitivity as a result of an increased binding valence of the detector molecules. We have now evaluated the performance of the new HBsAg rapid test (DRW-HBsAg) in comparison with a well-established commercial rapid test (Determine HBsAg; previously from Abbott Laboratories; now from Inverness Medical Innovations) and with a CE-marked enzyme immunoassay (EIA) (Hepanostika HBsAg Ultra; BioMérieux) as the gold standard. Testing of serially diluted in-house HBsAg-positive samples, the World Health Organization standard, and sensitivity and reference panels yielded an analytical sensitivity for the DRW test of 0.2 to 0.8 IU/ml across HBsAg serotypes. Evaluation with eight commercially available seroconversion panels showed that the DRW-HBsAg test detected HBsAg an average of 6.1 days (range, 3 to 8 days) earlier than the Determine assay (P = 0.0078). Test sensitivity was also examined with two low-titer HBsAg EIA-positive panels in Beijing, China. Whereas 100% of these samples were detected by the DRW-HBsAg test, only 15.0% (P < 0.0001) and 87.3% (P < 0.0001), respectively, were detected by the Determine HBsAg test. The performance of the DRW-HBsAg test was further evaluated with samples determined to be HBsAg positive or negative by the EIA in Conakry, Guinea, and Beijing, China. No significant difference in sensitivity between the DRW and Determine tests was apparent with the HBsAg EIA-reactive samples from Guinea (96.7% versus 94.4%, respectively) or China (99.46 versus 98.92%, respectively). The specificity of the Determine HBsAg test was slightly higher than that of DRW-HBsAg test (100 versus 99.2%, respectively) with samples from EIA-negative blood donors in China. In conclusion, the new DRW HBsAg rapid test is more sensitive than the Determine HBsAg test and is suitable for diagnostic and blood screening in resource-limited settings.
Figures


Similar articles
-
Performance of a new rapid test for the detection of hepatitis B surface antigen in various patient populations.J Clin Virol. 2014 Feb;59(2):89-93. doi: 10.1016/j.jcv.2013.11.010. Epub 2013 Dec 1. J Clin Virol. 2014. PMID: 24355522
-
Upconverting nanoparticle reporter-based highly sensitive rapid lateral flow immunoassay for hepatitis B virus surface antigen.Anal Bioanal Chem. 2021 Feb;413(4):967-978. doi: 10.1007/s00216-020-03055-z. Epub 2020 Nov 23. Anal Bioanal Chem. 2021. PMID: 33230700 Free PMC article.
-
Evaluation of a novel chemiluminescent microplate enzyme immunoassay for hepatitis B surface antigen detection.J Virol Methods. 2016 Feb;228:55-9. doi: 10.1016/j.jviromet.2015.11.013. Epub 2015 Nov 23. J Virol Methods. 2016. PMID: 26615806
-
New strategies for blood donor screening for hepatitis B virus: nucleic acid testing versus immunoassay methods.Mol Diagn Ther. 2006;10(2):77-91. doi: 10.1007/BF03256447. Mol Diagn Ther. 2006. PMID: 16669606 Review.
-
Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors?Transfus Clin Biol. 2004 Feb;11(1):26-32. doi: 10.1016/j.tracli.2003.12.003. Transfus Clin Biol. 2004. PMID: 14980546 Review.
Cited by
-
Chronic hepatitis B prevalence among children and mothers: results from a nationwide, population-based survey in Lao People's Democratic Republic.PLoS One. 2014 Feb 28;9(2):e88829. doi: 10.1371/journal.pone.0088829. eCollection 2014. PLoS One. 2014. PMID: 24586408 Free PMC article.
-
Point-of-Care Tests for Hepatitis B: An Overview.Cells. 2020 Oct 2;9(10):2233. doi: 10.3390/cells9102233. Cells. 2020. PMID: 33023265 Free PMC article. Review.
-
Diagnostic accuracy of tests to detect hepatitis B surface antigen: a systematic review of the literature and meta-analysis.BMC Infect Dis. 2017 Nov 1;17(Suppl 1):698. doi: 10.1186/s12879-017-2772-3. BMC Infect Dis. 2017. PMID: 29143619 Free PMC article.
-
Validation of rapid point-of-care (POC) tests for detection of hepatitis B surface antigen in field and laboratory settings in the Gambia, Western Africa.J Clin Microbiol. 2015 Apr;53(4):1156-63. doi: 10.1128/JCM.02980-14. Epub 2015 Jan 28. J Clin Microbiol. 2015. PMID: 25631805 Free PMC article.
-
Hepatitis D virus and hepatitis B virus infection in Amerindian communities of the Amazonas state, Colombia.Virol J. 2015 Oct 24;12:172. doi: 10.1186/s12985-015-0402-5. Virol J. 2015. PMID: 26497287 Free PMC article.
References
-
- Allain, J. P., D. Candotti, F. Sarkodie, and O. Opare-Sem. 2005. Lack of correlation between hepatitis B surface antigen and hepatitis B virus DNA levels in blood donors. Transfusion 451039-1040. - PubMed
-
- Allain, J. P., D. Candotti, K. Soldan, F. Sarkodie, B. Phelps, C. Giachetti, V. Shyamala, F. Yeboah, M. Anokwa, S. Owusu-Ofori, and O. Opare-Sem. 2003. The risk of hepatitis B virus infection by transfusion in Kumasi, Ghana. Blood 1012419-2425. - PubMed
-
- Allain, J. P., and H. H. Lee. 2005. Rapid tests for detection of viral markers in blood transfusion. Expert Rev. Mol. Diagn. 531-41. - PubMed
-
- André, F. 2000. Hepatitis B epidemiology in Asia, the Middle East and Africa. Vaccine 18(Suppl. 1)S20-S22. - PubMed
-
- Branson, B. M. 2003. Point-of-care rapid tests for HIV antibodies. J. Lab. Med. 27288-295.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical